A study to evaluate how safe and effective 0.5 mg FTY720 is in delaying disability progression if taken once daily, in patients with PPMS

Registry ID

EUCTR2012-000835-18

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE3

Sponsor

Novartis Pharma Services AG

Start date

2014-07-22

Completion date

2015-06-22

Last update

2026-08-16

Conditions

• Primary progressive multiple sclerosis.

Summary

To assess the long-term safety, tolerability, and efficacy (as measured by clinical and MRI parameters of disease activity) of fingolimod 0.5 mg/day in PPMS patients.

Locations

• , , Belgium
• , , UK
• , , Germany
• , , Finland
• , , Spain
• , , Sweden
• , , Italy
• , , Netherlands
• , , Hungary
• , , Czechia
• , , France
• , , Denmark
• , , Poland

View on source registry